FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891922087> ?p ?o ?g. }

• W2891922087 abstract "e16522 Background: Cs are commonly used in the treatment of mCRPC, because of their inhibitory effects on the secretion of ACTH and their palliative effects. Inhibition of ACTH results in downregulation of adrenal androgens. Cs may have a cytotoxic effect on prostate cancer cells, mediated in part by the downregulation of androgen receptors and the activation of glucocorticoid receptor-mediated signaling and downstream antiangiogenic activity. The rationale for adding Cs to D chemotherapy is for the management of symptoms and adverse events rather than for improving responses. D (without Cs) + ADT (androgen-deprivation therapy) vs ADT alone in castration-sensitive prostate cancer has resulted in significant increase in survival (NEJM, 2015). Cs has been reported to adversely influence OS during enzalutamide (NEJM, 2012). In the COU-AA-301 trial Cs use at baseline was an independent prognostic factor in multivariate analysis, but not in a stepwise selection model (JCO, 2013). Methods: We performed a retrospective analysis of 117 mCRPC pts treated with D. All pts had standard Cs premedication before D and 74 pts received prednisone 5 mg po BID, but 43 pts didn’t get continuous Cs therapy. Kaplan-Meier estimates and Cox regression model were used. Results: Pts characteristics were as follows: median age 66 yrs (range 48-81), Gleason score ≤6: 22pts, ≥7: 61pts. (34 NA). Altogether 1015 cycles of D were given, median 8 (range 2-27). Subsequent therapies were as follows: Abiraterone Acetate (AA) (75), Mitoxantrone (46), Xofigo (5), other chemotherapies (7), none (21). Pts receiving Cs had an inferior OS in all subgroups, although none was significant (Table). Only the Gleason score was an independent prognostic factor in multivariate analysis. Conclusions: Our data suggest, that D therapy withouth Cs is at least as effective as the combination. More data is neccesary to support the suspicion of negative influence of Cs on OS. Thus unnecesarry Cs treatment might be ommited. [Table: see text]" @default.
• W2891922087 created "2018-09-27" @default.
• W2891922087 creator A5000876847 @default.
• W2891922087 creator A5007654866 @default.
• W2891922087 creator A5010650581 @default.
• W2891922087 creator A5046043559 @default.
• W2891922087 creator A5051508644 @default.
• W2891922087 creator A5068554206 @default.
• W2891922087 creator A5069679822 @default.
• W2891922087 creator A5084994813 @default.
• W2891922087 date "2017-05-20" @default.
• W2891922087 modified "2023-09-29" @default.
• W2891922087 title "The effect of corticosteroid (Cs) use during docetaxel (D) treatment on overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC)." @default.
• W2891922087 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e16522" @default.
• W2891922087 hasPublicationYear "2017" @default.
• W2891922087 type Work @default.
• W2891922087 sameAs 2891922087 @default.
• W2891922087 citedByCount "0" @default.
• W2891922087 crossrefType "journal-article" @default.
• W2891922087 hasAuthorship W2891922087A5000876847 @default.
• W2891922087 hasAuthorship W2891922087A5007654866 @default.
• W2891922087 hasAuthorship W2891922087A5010650581 @default.
• W2891922087 hasAuthorship W2891922087A5046043559 @default.
• W2891922087 hasAuthorship W2891922087A5051508644 @default.
• W2891922087 hasAuthorship W2891922087A5068554206 @default.
• W2891922087 hasAuthorship W2891922087A5069679822 @default.
• W2891922087 hasAuthorship W2891922087A5084994813 @default.
• W2891922087 hasConcept C121608353 @default.
• W2891922087 hasConcept C126322002 @default.
• W2891922087 hasConcept C143998085 @default.
• W2891922087 hasConcept C2777899217 @default.
• W2891922087 hasConcept C2778971682 @default.
• W2891922087 hasConcept C2779256933 @default.
• W2891922087 hasConcept C2780192828 @default.
• W2891922087 hasConcept C2781190966 @default.
• W2891922087 hasConcept C3019894029 @default.
• W2891922087 hasConcept C71315377 @default.
• W2891922087 hasConcept C71924100 @default.
• W2891922087 hasConceptScore W2891922087C121608353 @default.
• W2891922087 hasConceptScore W2891922087C126322002 @default.
• W2891922087 hasConceptScore W2891922087C143998085 @default.
• W2891922087 hasConceptScore W2891922087C2777899217 @default.
• W2891922087 hasConceptScore W2891922087C2778971682 @default.
• W2891922087 hasConceptScore W2891922087C2779256933 @default.
• W2891922087 hasConceptScore W2891922087C2780192828 @default.
• W2891922087 hasConceptScore W2891922087C2781190966 @default.
• W2891922087 hasConceptScore W2891922087C3019894029 @default.
• W2891922087 hasConceptScore W2891922087C71315377 @default.
• W2891922087 hasConceptScore W2891922087C71924100 @default.
• W2891922087 hasLocation W28919220871 @default.
• W2891922087 hasOpenAccess W2891922087 @default.
• W2891922087 hasPrimaryLocation W28919220871 @default.
• W2891922087 isParatext "false" @default.
• W2891922087 isRetracted "false" @default.
• W2891922087 magId "2891922087" @default.
• W2891922087 workType "article" @default.